Palvella Therapeutics posted a corporate presentation outlining positive Phase 3 data for its lead candidate QTORIN™ 3.9% rapamycin gel in microcystic lymphatic malformations and detailing upcoming regulatory and clinical milestones across its rare disease pipeline.
Key takeaways
Positive Phase 3 data announced February 2026 for QTORIN™ 3.9% rapamycin gel in microcystic lymphatic malformations, with 86% of patients rated 'Much Improved' or 'Very Much Improved'.
NDA submission planned for second half of 2026 for microcystic lymphatic malformations, with potential FDA approval in first half of 2027.
Breakthrough Therapy Designation application expected to be submitted in second quarter of 2026 for cutaneous venous malformations.
Phase 2 trial initiation ahead of schedule expected in second quarter of 2026 for clinically significant angiokeratomas.
Company estimates over 30,000 diagnosed U.S. patients for microcystic lymphatic malformations and over 75,000 for cutaneous venous malformations.
QTORIN™ platform enables pipeline expansion to six rare diseases with multiple high-impact milestones anticipated over the next 12+ months.